Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Receptor tyrosine kinase inhibitors as anti-angiogenic agents.

Kim DW, Lu B, Hallahan DE.

Curr Opin Investig Drugs. 2004 Jun;5(6):597-604. Review.

PMID:
15242247
2.

Antiangiogenic therapy in malignant glioma: promise and challenge.

Sathornsumetee S, Rich JN.

Curr Pharm Des. 2007;13(35):3545-58. Review.

PMID:
18220791
4.

Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.

Broxterman HJ, Georgopapadakou NH.

Drug Resist Updat. 2005 Aug;8(4):183-97. Epub 2005 Sep 9.

PMID:
16154800
5.

Therapeutically targeted anticancer agents: inhibitors of receptor tyrosine kinases.

García-Echeverría C, Fabbro D.

Mini Rev Med Chem. 2004 Mar;4(3):273-83. Review.

PMID:
15032674
6.

The anti-angiogenic and anti-tumor activity of synthetic phenylpropenone derivatives is mediated through the inhibition of receptor tyrosine kinases.

Lee JS, Kang Y, Kim JT, Thapa D, Lee ES, Kim JA.

Eur J Pharmacol. 2012 Feb 29;677(1-3):22-30. doi: 10.1016/j.ejphar.2011.12.012. Epub 2011 Dec 20.

PMID:
22200628
7.

Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents.

Hartman GD, Fraley ME, Bilodeau MT.

Expert Opin Investig Drugs. 2002 Jun;11(6):737-45. Review.

PMID:
12036418
9.

Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics.

Zhu Z, Bohlen P, Witte L.

Curr Cancer Drug Targets. 2002 Jun;2(2):135-56. Review.

PMID:
12188915
10.

Targeting angiogenesis in head and neck cancer.

Seiwert TY, Cohen EE.

Semin Oncol. 2008 Jun;35(3):274-85. doi: 10.1053/j.seminoncol.2008.03.005. Review.

PMID:
18544442
11.

Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases.

Mazitschek R, Giannis A.

Curr Opin Chem Biol. 2004 Aug;8(4):432-41. Review.

PMID:
15288254
12.

The use of tyrosine kinase inhibitors in modifying the response of tumor microvasculature to radiotherapy.

Lu B, Shinohara ET, Edwards E, Geng L, Tan J, Hallahan DE.

Technol Cancer Res Treat. 2005 Dec;4(6):691-8. Review.

PMID:
16292890
13.

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.

Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei RQ, Li J, Guo J, Bousquet PF, Ghoreishi-Haack NS, Wang B, Bukofzer GT, Wang YC, Stavropoulos JA, Hartandi K, Niquette AL, Soni N, Johnson EF, McCall JO, Bouska JJ, Luo Y, Donawho CK, Dai Y, Marcotte PA, Glaser KB, Michaelides MR, Davidsen SK.

Mol Cancer Ther. 2006 Apr;5(4):995-1006.

14.

Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold.

Kissau L, Stahl P, Mazitschek R, Giannis A, Waldmann H.

J Med Chem. 2003 Jul 3;46(14):2917-31.

PMID:
12825933
15.

Novel anticancer drug discovery.

Buolamwini JK.

Curr Opin Chem Biol. 1999 Aug;3(4):500-9. Review.

PMID:
10419854
16.

New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

Faivre S, Djelloul S, Raymond E.

Semin Oncol. 2006 Aug;33(4):407-20. Review.

PMID:
16890796
17.

Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family.

Dalal S, Berry AM, Cullinane CJ, Mangham DC, Grimer R, Lewis IJ, Johnston C, Laurence V, Burchill SA.

Clin Cancer Res. 2005 Mar 15;11(6):2364-78.

18.

Targeting angiogenesis for the treatment of sarcoma.

Balasubramanian L, Evens AM.

Curr Opin Oncol. 2006 Jul;18(4):354-9. Review.

PMID:
16721130
20.

Tyrosine kinase receptors as attractive targets of cancer therapy.

Bennasroune A, Gardin A, Aunis D, Crémel G, Hubert P.

Crit Rev Oncol Hematol. 2004 Apr;50(1):23-38. Review.

PMID:
15094157

Supplemental Content

Support Center